Daily Archives: April 15, 2021

(J. the Jewish News of Northern CaliforniaviaJTA) Early in the COVID-19 pandemic, while some people were dabbling with new hobbies, Rabbi Zac Kamenetz was going all in on a lifelong fantasy.

Kamenetz has a vision. He dreams of a world in which the trauma of the Jewish past can be healed through psychedelic experiences, a world in which chemically assisted mystical encounters are a normative part of Jewish spirituality.

Someday I see a space, maybe in the East Bay, where people can have safe and supported psychedelic experiences individually, and then integrate those experiences in a community that is invested in the application of mystical experiences with other people, hetoldJ. the Jewish News of Northern California, in 2019. This is total science fiction because it doesnt exist.

Get The Jewish Standard Newsletter by email and never miss our top storiesFree Sign Up

It does now. After losing his job as the director of Jewish learning and living at the Jewish Community Center of San Francisco during a round of pandemic layoffs, Kamenetz decided to go for it. He foundedShefa, which means flow in Hebrew; the organizations tagline is Connect With Divine Flow.

In less than a year, Kamenetz has secured funding from Jewish donors, as well as Dr. Bronners Family Foundation (as in Dr. Bronners Magic Soaps, the earthy brand with fine print all over the bottle) and the Riverstyx Foundation,which funds a number of psycho-spiritual projects.

He also has begun to hold regular integration circles, support group-like gatherings in which fellow travelers discuss and come to terms with their psychedelic experiences.

Later this spring Kamenetz is staging a two-day event that promises to put Shefa on the map the first-everJewish Psychedelic Summit. Its a collaboration among Kamenetz; Madison Margolin, editor of the psychedelics magazineDoubleBlind;and Natalie Lyla Ginsberg, director of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies.

Ginsbergs group, MAPS, has deep Jewish roots. Its founder, Rick Doblin,was inspired by a dream about surviving the Nazisto devote his life to promoting psychedelics as a cure for human ills and an insurance policy against another Holocaust. The organization has supported research and policy to advance psychedelics as a therapeutic tool.

Shefas summit will zoom in on uniquely Jewish questions related to psychedelics. To be held virtually with four sessions each on May 2-3, the summit will bring together dozens of rabbis, scholars, artists and more for panels with topics such as Did Psychedelics Play a Role in Ancient Jewish Practice? What Draws so Many Jews to India? and Jewish Trauma and Psychedelic Therapy: What Is Culturally Informed Care?

Psychedelic substances whether organic, such as psilocybin (magic mushrooms) or synthetic (such as LSD) are illegal virtually everywhere in the country, although some have been decriminalized to varying degrees in Oakland and Santa Cruz, California; Denver, Colorado; Ann Arbor, Michigan; and the state of Oregon. But that hasnt stopped researchers and other practitioners some funded by MAPS from beginning to delve into themedical applicationsof these substances, such as treating PTSD, anxiety, depression and other conditions.

Kamenetz has had two experiences with psilocybin, and both were done legally as part of a Johns Hopkins University study of psychedelic experiences in clergy of various religions.

Those experiences were among the most powerful of his life, he said, and convinced him of the need for psychedelic-assisted healing in the Jewish community.

Im one of the very few people who can say theyve had a legal experience with psychedelics in this country, Kamenetz said. To be able to speak freely about it without the stigma because its not just people talking about doing illegal things its allowed people to start having a more open conversation about it. When theres the opportunity to hear from someone who did this in a legal environment, people will listen more.

And for Jews who have already been working with or using psychedelics, Kamenetz is proud to be creating a platform where they can talk about it more openly.

I think weve gotten ahead of the market, he said. If it wasnt me, it wouldve been someone else.

Ben, a 34-year-old graduate student who didnt want to use his full name, is one of the many Jews who have used psychedelic substances. Hes attended two Shefa integration circles, 90-minute affairs that can include some Jewish chanting, brief text study and discussion of personal psychedelic experiences.

He appreciates the open, nonhierarchical vibe.

People are encouraged to share about their experiences, ask questions, receive feedback, Ben said.

I have a significant and long-standing psychedelic background. I have had a lot of conversations about it with similarly inclined Jews.

Ben first heard about Shefawhen Kamenetz was interviewed on the Judaism Unbound podcast.

I knew right away this is a conversation I want to be part of, he said. And I sort of got the same sense from a lot of other people, a shared sense that it was important to talk about and do and explore this, to create spaces where we can talk about it.

When the Jewish Psychedelic Summit was announced, Ben didnt even bother looking at the list of speakers.

I just saw the name [of the conference] and said sign me up, he said, though he admits hes excited about hearing from Rodger Kamenetz, the poet and author of The Jew in The Lotus.

RabbiKamenetz (no relation) is excited, too.

Weve got this big Jewish family of psychedelic enthusiasts who are coming and contributing to making this thing happen, he said. Thats why it feels so significant to me. Ive never been part of something that really felt like a movement.

See the article here:

First Jewish psychedelics conference looks to put spiritual drug use on the map - The Jewish Standard

After Joe Biden, drugsspecifically psychedelicswere the biggest winner of the 2020 election: Oregon legalized psilocybin mushrooms for mental health treatment; Washington D.C. decriminalized them; and New Jersey introduced a reform bill to drastically reduces penalties for the possession of psychedelics, which later passed.

The changes in these laws follow what Anderson Cooper coined a psychedelic renaissance, during a 60 Minutes episode in 2019. Nowadays, everyone from Gwyneths Goop gals to the worlds greatest lab partner Michael Pollan is experimenting with drugs that most of us used to only be able to find at a Phish festival. This widened acceptance is generally considered a step in the right direction. After all, studies testing whether psychedelic compounds like MDMA and psilocybin can reduce depression, anxiety, and PTSD have repeatedly shown promising results.

But as attitudes about psychedelics change and access to them inevitably increases, some members of the psychedelic community are pausing to ask themselves an important question: What kind of movement do we want to be? One organization with a vision in mind is Fireside Project, a San Francisco-based nonprofit that has engineered the worlds first psychedelic peer-support line.

Think of a psychedelic peer-support line as a hybrid of a mental health warmline that people can call or text to receive emotional support during a time of need, and a Reddit thread about peyote-induced visuals. Its essentially a digital tripsitter that anyone with the wits and wherewithal to use a phone while blitzed can access. Firesides mission is simple but surreal: Help all people minimize the risks and fulfill the potential of their psychedelic experiences.

Elaine Chung + Fireside Project

According to Fireside co-founder Joshua White, that all people bit is an important detail. When we think about psychedelics, often there's a certain person that comes to mind, he said when we spoke earlier this spring. Were very intentional about saying all communities, all people. In other words, Fireside isnt just for your friend from college who smells like a head shop; nor is it only for burners and yogis, or the new age, attention-hacking microdosers of Silicon Valley. Those folks are free to call in, of course, but they arent who White had in mind when he set out to build Fireside. Rather, he was hoping to help individuals who might not have the means to safely access and consume psychedelics within the very expensive, burgeoning medical model. (If and when the FDA approves MDMA for the treatment of depression and anxiety, it could cost anywhere from $12,000 to $20,000, by one estimate.)

"How to Change Your Mind"

What White wants to do is create a low-threshold alternative to the walled-off medical model that looms over the psychedelic community. His hope is that Fireside will be one part of a mycelial network that includes multiple free psychedelic therapeutic services, which can step in and provide assistance to the many people who studies have shown are increasingly using psychedelics to self-medicate. To help ensure that Firesides services are highly accessible, White solicited donations from members of his community. He also received funding from David Bronner, CEO of the organic soap company Dr. Bronners. Thanks to that money, the Fireside line is free and open to any individual within the United States. (For its first year, Fireside will operate during select hours five days a week. If things go well and additional funding comes through, it will operate 24/7.)

Starting April 14, anyone who is having a psychedelic experience can key in Firesides number and text, chat, or speak live with one of Firesides 30 trained volunteers. That includes people who are in the midst of a trip, looking to process a past trip, or currently supporting someone through an experience (for instance, a tripsitter who is unsure of how to create a calm environment for a friend). The callers can remain anonymous if they like and will not be asked what substance they are on. (If someone calls for reasons unrelated to a psychedelic experience, Fireside will refer them to other resources.)

For those who have had the humbling experience of tripping without a safety net, the essentialness of a service like Fireside is all too obvious. Put simply, things can get intense fast. Someone who can reassure you that, yes, your hands look normal, and, no, your houseplant isnt giving you side-eye, is often what prevents a trip from going sideways. And in case things do go sidewayspsychedelics can surface powerful, sometimes painful memories or visionsFiresides volunteers are prepared to help with tips, perspective, and strategies aimed at rowing an individual back to shore and grounding them in the moment. But you dont have to be having a bad trip to access Firesides services. You can also call in to riff on what you are seeing and share the joy that you may find is bubbling inside you.

Crucially, the volunteers are a well-trained and diverse bunch. They represent 14 countries, 11 languages, 16 ethnicities, and a range of gender and sexual identities. Each one of them has undergone 36 hours of training with Firesides Support Line Director, Adam Rubin, and its co-founder and Cultivator of Beloved Community, Hanifa Nayo Washington. The sessions Rubin and Washington lead focus on practical skills like reflective listening, and sociocultural topics like systematic racism, oppression, and equity, so that the volunteers are prepared to meet people where they are at, said Washington.

Having an inclusive class of volunteers that represented the entire United States was Washingtons top priority for Fireside, one born from personal experience. There are so many things that come up in a psychedelic session, she explained, before describing the many times she has revisited the pain and trauma of being a Black woman in this country while on psychedelics and surrounded by white men. Those experiences, while meaningful, led her to conclude that when it came to creating a welcoming and safe environment for callers, relatability and affinity mattered.

Her understanding mirrors a growing, community-wide realization. Recently, the Chacruna Institute for Psychedelic Plant Medicine launched a Racial Equity and Access Committee, which seeks to ensure that historically marginalized communities have access to and are included in psychedelic research. The field has its work cut out for it; a 2018 analysis of past psychedelic studies revealed that 82 percent of participants were non-Hispanic white and only 2.5 percent were Black.

After a psychedelic experience, I feel like there's a light inside of me, and the more I talk to people about my experience, the longer that light stays lit.

White and Washington have invested so heavily in their volunteers because they are the heart of the Fireside Project. They give callers the opportunity to enrich their psychedelic encounters through connection and integration, the practice of exploring and synthesizing the insights that arise from a psychedelic experience for everyday life. White described this integration as a muscle that in a lot of ways has not been flexed before. Despite being a fundamental element of communing with plant-based medicines in indigenous ceremonies, in American popular culture, the practice of integration rarely occurs outside of wellness circles. As a result, its a privilege that few people can access or afford.

White views this as a missed opportunity to make the most out of a trip. After a psychedelic experience, I feel like there's a light inside of me, and the more I talk to people about my experience, the longer that light stays lit, he said. The Fireside Project will attempt to expand integration by offering weekly follow-up calls, texts, or live chats to anyone who originally called in during a psychedelic experience. To have a person who you don't know call you and check in on you every single week to ask about how your integration process is going, will, in our view, revolutionize how integration occurs, said White.

Now its time to put that vision to the test. The stakes are high for Firesides two co-founders, who met at Burning Man in 2019 and have since devoted most of their time and energy into creating Fireside. White in particular has a lot on the line. In a leap of faith that he credits ayahuasca and therapy for helping him make, he quit his job as a lawyer to devote himself full-time to the psychedelic community. But as Washington reminded him when the three of us spoke, the cause couldnt be more worthwhile. [Psychedelics] have the potential to heal a lot of trauma," she said. "Not having barriers to wellness is super important. It's our birthright to heal.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Read the original post:

Fireside Project Is a New Psychedelic Support Line Working to Ensure You Have a Good Trip - Esquire

As interest in psychedelics continues, one company is taking the experience a step further with an app that helps users reach wellness goals.

The frontier of psychedelics-based treatments is expanding as these substances continue to gain credibility in the eyes of the medical community.

More and more novel psychedelic medicine companies are pitching the potential of improved mental health treatments through the use of psychedelic compounds such as psilocybin.

Alongside these groundbreaking medical options, theres been an uptick in devices and phone applications related to the psychedelics lifestyle.

For example, microdosing has gained popularity among tech workers, and now theres an app for the practise, which involves consuming psychedelics in small doses as a way to improve day-to-day life.

The psychedelics apps available vary in scope and rigor, but one app in particular offers users the ability to interact one-on-one with experts who will guide them through psychedelics-based experiences.

Mindleap is an app where users can book video appointments with specialists and get help with their psychedelics journey. Appointments go for just under an hour, with prices set by the expert at hand.

Users can also employ wearable devices like an Apple Watch to share and monitor information about their day-to-day lives, particularly their experience and relationship with psychedelic substances. They can also set wellness goals for their state of mind and lifestyle.

You can use that information for yourself, you can choose to share it with your mental health specialists so then the actual therapy that youre receiving is more data driven, Nikolai Vassev, founder and CEO at Mindleap Health, told the Investing News Network (INN).

Vassev spoke at length about what he sees as the benefits of the entire psychedelics revolution and the role his companys app can play within that shift.

He said that while the potential held within the most advanced clinical trials for psychedelic substances is staggering, their results and any changes they may bring will take time. What people can use now is guidance in the therapeutic use of the psychedelic substances they have available.

Mindleap is an app for people that are curious about psychedelics, wanting to either microdose, prepare for an experience or integrate an experience into actual changes in their life, Vassev said.

The tech executive told INN the inspiration for Mindleap came to him after visiting a psychedelics retreat in the Netherlands. His goal was for the app to reach 50,000 users by the end of 2020, alongside 100 specialists available for users.

Thanks to his background with a data analytics firm, Vassev put two and two together once he realized that the vast amount of interest in this lifestyle would then create vast amounts of data.

I saw this kind of missing piece of lack of access to psychedelic integration specialists and psychedelic experts, and I wanted to build this platform for it, he told INN.

While wellness apps and the connection between healthier lifestyles and everyday technologies are nothing new, the idea of marrying the use of psychedelics with tech options is in the early stages.

Earlier this year, psychedelics firm Mind Cure Health (CSE:MCUR,OTCQB:MCURF) launched its own digital solutionfor wellness optimization and support resources.

Dubbed iSTRYM, this app allows users to monitor their experiences with psychedelics and will eventually help feed into the treatment they receive, according to the firm.

Mind Cure confirmed the app will collect a variety of data points from its patient users after a therapy session has taken place, such as weather, location, mood and heart rate.

Mind Cure Chief Technology Officer Geoff Belair said the app will implement artificial intelligence to hone how the app works for users.

One of the key differentiators in our proprietary tech piece is the implementation of artificial intelligence, working in the background, to taxonify the uncategorized daily inputs from patients into tangible assets that will then inform treatments, Belair said in a statement.

The app will build out its database of information based on patients, clinicians and therapists.

The adoption of psychedelics and the recognition of their benefits appear to be driving the introduction of new technology to the psychedelics space.

While the potential of these apps remains to be seen, its clear that excitement for the entire psychedelics revolution is beginning to bleed over into different sectors.

Dont forget to follow us @INN_LifeSciencefor real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Go here to see the original:

How This App Can Play a Role in the Psychedelics Industry | INN - Investing News Network

Early in the Covid-19 pandemic, while some people were starting new hobbies, Rabbi Zac Kamenetz was starting a groundbreaking new organization, one he has long fantasized about.

Kamenetz has a vision. He dreams of a world in which the trauma of the Jewish past can be healed through psychedelic experiences, a world in which chemically assisted mystical encounters are a normative part of Jewish spirituality.

Describing it to J. in 2019, he said, Someday, I see a space, maybe in the East Bay, where people can have safe and supported psychedelic experiences individually, and then integrate those experiences in a community that is invested in the application of mystical experiences with other people. This is total science fiction because it doesnt exist.

It does now. After losing his job at the Jewish Community Center of San Francisco during a round of pandemic layoffs, Kamenetz decided to go for it. He founded Shefa, which means flow in Hebrew; the organizations tagline is Connect With Divine Flow.

In less than a year, Kamenetz has secured funding from Jewish donors, as well as Dr. Bronners Family Foundation (as in Dr. Bronners Magic Soaps, the earthy brand with fine print all over the bottle) and the Riverstyx Foundation, which funds a number of psycho-spiritual projects.

He also has begun to hold regular integration circles, support group-like gatherings in which fellow travelers discuss and come to terms with their psychedelic experiences.

On March 26, Kamenetz announced a two-day event this spring that promises to put Shefa on the map the first ever Jewish Psychedelic Summit. Its a collaboration between Kamenetz; Natalie Lyla Ginsberg, director of policy and advocacy at the preeminent Multidisciplinary Association for Psychedelic Studies; and Madison Margolin, editor of the psychedelics magazine DoubleBlind.

To be held virtually with four sessions on May 2 and four more on May 3, the summit will bring together dozens of rabbis, scholars, artists and more for panels with topics such as Did Psychedelics Play a Role in Ancient Jewish Practice? What Draws so Many Jews to India? and Jewish Trauma and Psychedelic Therapy: What Is Culturally Informed Care?

Psychedelic substances whether organic, such as psilocybin (magic mushrooms) or synthetic (such as LSD) are illegal virtually everywhere in the country, although some have been decriminalized to varying degrees in Oakland, Santa Cruz, Denver, Ann Arbor, Michigan, and the state of Oregon. But that hasnt stopped researchers and other practitioners from beginning to delve into the medical applications of these substances, such as treating PTSD, anxiety, depression and other conditions.

Kamenetz has had two experiences with psilocybin, and both were done legally as part of a Johns Hopkins University study of psychedelic experiences in clergy of various religions.

Those experiences were among the most powerful of his life, he said, and convinced him of the need for psychedelic-assisted healing in the Jewish community.

Im one of the very few people who can say theyve had a legal experience with psychedelics in this country, Kamenetz said. To be able to speak freely about it without the stigma because its not just people talking about doing illegal things its allowed people to start having a more open conversation about it. When theres the opportunity to hear from someone who did this in a legal environment, people will listen more.

And for Jews who have already been working with or using psychedelics, Kamenetz is proud to be creating a platform where they can talk about it more openly.

I think weve gotten ahead of the market, he said. If it wasnt me, it wouldve been someone else.

Ben, a 34-year-old graduate student who didnt want to use his full name, is one of the many Jews who have used psychedelic substances. Hes attended two Shefa integration circles, 90-minute affairs that can include some Jewish chanting, brief text study and discussion of personal psychedelic experiences.

He appreciates the open, nonhierarchical vibe. People are encouraged to share about their experiences, ask questions, receive feedback, Ben said.

I have a significant and long-standing psychedelic background, he added. I have had a lot of conversations about it with similarly inclined Jews.

Ben first heard about Shefa when Kamenetz was interviewed on the Judaism Unbound podcast. I knew right away this is a conversation I want to be part of, he said. And I sort of got the same sense from a lot of other people, a shared sense that it was important to talk about and do and explore this, to create spaces where we can talk about it.

When the Jewish Psychedelic Summit was announced, Ben didnt even bother looking at the list of speakers. I just saw the name [of the conference] and said sign me up, he said though he admits hes excited about hearing from Rodger Kamenetz, the poet and author of The Jew in The Lotus.

Rabbi Kamenetz (no relation) is excited, too. Weve got this big Jewish family of psychedelic enthusiasts who are coming and contributing to making this thing happen, he said. Thats why it feels so significant to me. Ive never been part of something that really felt like a movement.

Read the original post:

The Jewish psychedelic movement takes flight J. - The Jewish News of Northern California

HUNTINGTON BEACH, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- The Recover, a national news provider for mental health and substance abuse, recently began releasing news about psilocybin and their potential health benefits.

Psychedelic drugs such as magic mushrooms have long-lasting medical and spiritual benefits, according to a new study. Magic Mushroom Landscape has established a company to evaluate new treatments related to psychedelics and mental health.

The Food and Drug Administration (FDA) has approved the use of the hallucinogenic active ingredient psilocybin, which is known to strengthen the mind of magic mushrooms - and thus alter their powers. In November, the FDA issued the first psychedelic drug ever approved by the FDA, a hallucinogenic drug in the form of prilocaine, one of two types of psychedelic drugs, and the second - the most common form, LSD - because of its impact on mental health. A controlled study by researchers at the University of North Carolina at Chapel Hill found the substance is safe for human consumption, bringing researchers closer to developing a psilocybin-based treatment for depression, the study said.

Although psilocybin is illegal at the federal level in the US, it is still considered legal in New Mexico to possess and grow mushrooms as long as they are not dried, and only licensed therapists and manufacturers will be allowed to grow, extract from, synthesize the drug, set up psilocybin therapy centers, or offer therapies. Such uses will be strictly regulated, however; only those licensed as therapists or manufacturers can grow and extract the fungus, but only to the extent that they can produce and synthesize it. However, because the spores do not contain any chemicals specifically regulated by federal law, their spores are perfectly legal for possession in the United States.

Psilocybin fungi are administered to humans by researchers who test the efficacy of the substance and administering them in a medically controlled environment with a trusted therapist could be very helpful.

The team found that people who had recently taken psilocybin, better known as magic mushrooms, were more likely to report having a transformative experience. In fact, several studies have so far found evidence of the benefits of using psilocin fungi to treat depression in combination with supportive therapy. Other studies have shown that the psychedelic psilocybin in the mushrooms help to change the way information travels through the brain. While regulators have fought against the use of psychedelic drugs such as MDMA (ecstasy) and LSD (LSD), researchers have found that patients can provide psychological support through the use of these psychedelics, especially for people with mental health problems.

In short, magic mushrooms can get your brain back to where it was before the feelings of depression set in. If you have legitimate access to psilocybin mushrooms, it gives you access to a whole new world of possibilities for treating mental illness.

Meanwhile, psilocybin, the psychoactive component of magic mushrooms, has been shown to be helpful in psychotherapy, and research suggests that it can be as effective in combination with psychotherapy as traditional treatments for depression and other mental illnesses. There is debate as to whether psychologists can use psilocin and similar hallucinogens to treat depression or not.

The experience with magic mushrooms can be traumatic for users who experience a bad trip, and those with these diseases suffer more if they do not use magic mushrooms for a long time. Those who try psilocybin mushrooms for the first time will inevitably worry at some point that they have a "bad journey" that can happen. Knowing that you have a controlled substance can also increase unpleasant emotions such as paranoia during the experience with magic mushrooms. Without a trained mental health worker to help process the event, the outcome could be bad.

There is no evidence that the fungi cause stomach bleeding, but there is no research on what happens after taking psilocybin fungi at all. However, these findings are supported by growing evidence supporting the mental health benefits of psilocin, such as reducing anxiety and depression.

If someone has psychedelic problems in the family after using, they may need to avoid taking psychedelics. Due to the high content of compounds found in psychedelic magic mushrooms, cancer patients may exhibit symptoms similar to those of people without cancer, such as nausea, vomiting, diarrhea and vomiting.

Scientists at leading institutions have acknowledged that psilocybin fungi, in small quantities under medical supervision, have the potential to treat severe mental disorders. Disbelief is widespread among those who have learned that it can cause a sustained remission of depression that lasts for months or years. The fast-acting nature of psychedelic magic mushrooms and their effects are attractive because antidepressant drugs and therapies can take weeks before patients feel the benefits.

Dr Robin Carhart-Harris led the first study to test how psilocybin mushroom therapies work compared to leading antidepressants. The study, completed in 2016, is the first modern study to specifically address treatment for resistant depression with psychedelics, which naturally occur in about 200 types of fungi. There it is still a mystery why fungi developed these psychedelic chemicals in the first place. Psilocin mushrooms are eaten in dried form, and most people agree that they do not taste good.

The Recover offers information about possible treatment options for those who suffer from mental illness or substance abuse. For information regarding addiction treatment centers, visit their website or contact their 24hr helpline.

Contact Info:

Author: McKenzie Santa Maria

Organization:https://therecover.com/

Address: Orange County, CA 92648

Phone: (888) 510-3898

Read more here:

Psilocybin Mushrooms Use For Mental Health Research By The Recover - GlobeNewswire

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Women havecontributed greatly to the psychedelics industry, accomplishing incredible research and work in the field, despite being maligned in serious ways for just being involved. Given that International Womens Month has just ended, the timing seems ideal to shine a spotlight on women pioneers of psychedelics, along with a focus on what exactly held them back.

Women have had to jump through hurdles that did not exist for their male counterparts as well as bypass barriers in various industries and fields, including the field of psychedelic research. Knowledge of history or sometimes just personal experience has shown that the presence of women has been discouraged&

Read More >>

NOTE TO INVESTORS:The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the companys newsroom athttps://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) createsPsychedelicNewsBreaksdesigned to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text Groovy to 21000 (U.S. Mobile Phones Only)

For more information please visithttps://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW?Ask our Editor

PsychedelicNewsWire (PNW)San Francisco, Californiawww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicWire.com

PsychedelicNewsWire is part of theInvestorBrandNetwork.

Go here to see the original:

Women in the Psychedelic Field and the Barriers That Held Them Back - StreetInsider.com

Utilizing Speak Ai's technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy

VANCOUVER, BC, April 13, 2021 /PRNewswire/ -Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership with Speak Ai Inc. ("Speak Ai"). The Canadian-based technology company helps individuals and organizations analyze media, language, and metadata to automatically generate valuable insights through machine learning. MINDCURE will be integrating the platform's capabilities into iSTRYM, and will also work with Speak Ai to develop proprietary, technology-based mental health solutions.

By combining audio, video, and text analysis with metadata in a single platform, Speak Ai has developed a comprehensive solution for generating personalized insights to improve research and personal wellbeing. Their technology has been honed over several years of development, research, and experience, and the organization has built a strong reputation within the psychedelic community.

"We are proud to partner with MINDCURE today to help build iSTRYM into a powerful solution for therapists and patients around the world," said Tyler Bryden, Speak Ai Founder. "I have had the privilege to witness the potential of psychedelic-assisted therapies in my own life and in the lives of amazing people around me who are healing from anxiety, depression, PTSD, traumatic brain injuries, and more."

This partnership will result in driving data for iSTRYM, taking unstructured data, and creating structure and metrics for the platform integration. Natural language processing with machine learning allows MINDCURE to drive insights for the therapist and patient. This information is often difficult to capture using traditional methods during the course of therapy.

"By developing solutions with empathy, we can improve the level of care to help people avoid, navigate through and recover from crises. We share the belief with MINDCURE that technology can play a major role in enabling these potentially life-changing and individual therapies to succeed at scale," continued Bryden.

"We are excited to work with Tyler and the team at Speak Ai because of their intimate knowledge of the value of technology in the therapeutic and integration process within psychedelics and the traditional therapeutic model," said MINDCURE CEO and President Kelsey Ramsden. "We will be building custom integrations with Speak Ai for the iSTRYM platform that allow us to marry sentiment with biometric data, location, weather, and a variety of other variables to help optimize our integration protocols and provide individuals with quantified care at scale globally, all with the stated goal of advancing Mental Wealth, rooted in data."

About Speak Ai Inc.

Speak Aiis a technology company harnessing the power of AI to help individuals and organizations transform their media into incredible assets for growth. By combining audio, video, and text analysis with metadata in a single platform, the Speak Ai team has developed a comprehensive solution for generating personalized insights that improves research and wellbeing.

Speak Ai works with well-established organizations like the London Health Sciences Centre and Ryerson University to improve recording systems, create transcripts, analyze audio and video quicker and less expensively, and provide an interactive media interface to easily navigate through long recordings. One of the researchers from LHSC said: "This is a complete paradigm shift for how we do research."

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of DirectorsKelsey Ramsden, President & CEOPhone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute "forward-looking information" within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Speak Ai developing proprietary mental health technology-based solutions for MINDCURE; iSTRYM becoming a must-have solution for therapists and patients around the world; this partnership driving data for iSTRYM; MINDCURE significantly improving the level of care, help people avoid and recover from crises and enable them to reach their fullest potential; and MINDCURE advancing Mental Wealth, rooted in data.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Speak Ai will develop proprietary mental health technology-based solutions for MINDCURE; iSTRYM will become a must-have solution for therapists and patients around the world; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE's industry and MINDCURE's business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE's investments, results of operations, financial condition, and MINDCURE's ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Speak Ai may not develop proprietary mental health technology-based solutions for MINDCURE; iSTRYM may not become a must-have solution for therapists and patients around the world; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under "Risk Factors" in MINDCURE's final prospectus which is available on SEDAR at http://www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

View post:

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform - PRNewswire

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

A third city in Massachusetts, Northampton, haspassed an initiativeto make the distribution, use and possession of various psychedelics, such as ayahuasca and psilocybin, one of the lowest priorities of law enforcement in the area. Prior to this, the cities ofCambridgeand Somerville had also approved measures to effectively decriminalize psychedelics.

The Northampton City Council approved the measure, which also stipulates that no police or government funds should be utilized in enforcing laws that criminalize individuals for the possession or use of entheogenic fungi and plants. The city council voted on the resolution&

Read More >>

NOTE TO INVESTORS:The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the companys newsroom athttps://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) createsPsychedelicNewsBreaksdesigned to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text Groovy to 21000 (U.S. Mobile Phones Only)

For more information please visithttps://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW?Ask our Editor

PsychedelicNewsWire (PNW)San Francisco, Californiawww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicWire.com

PsychedelicNewsWire is part of theInvestorBrandNetwork.

Read more:

Another City in Massachusetts Approves Measure to Decriminalize Psychedelics - StreetInsider.com